EULAV Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.3M Sell
8,910
-100
-1% -$118K 0.37% 79
2026
Q2
$10.8M Sell
9,010
-500
-5% -$511K 0.35% 79
2026
Q1
$8.75M Hold
9,510
– – 0.28% 91
2025
Q4
$10.2M Buy
9,510
+10
+0.1% +$9.6K 0.27% 98
2025
Q3
$7.25M Hold
9,500
– – 0.17% 114
2025
Q2
$7.41M Buy
+9,500
New +$7.38M 0.17% 112
2014
Q2
– Sell
-22,500
Closed -$1.32M – 398
2014
Q1
$1.32M Hold
22,500
– – 0.07% 298
2013
Q4
$1.15M Buy
22,500
+3,000
+15% +$150K 0.06% 317
2013
Q3
$981K Sell
19,500
-500
-3% -$26.2K 0.06% 331
2013
Q2
$982K Buy
+20,000
New +$1.09M 0.06% 335

Other funds holding LLY

EULAV Asset Management's LLY Position: Q3 2026 in Review

EULAV Asset Management reduced its Eli Lilly (LLY) stake by 1.1% in Q3 2026, selling an estimated $118K and leaving 8,910 shares worth $10.3M. The position accounts for 0.37% of the portfolio, ranked #79.

EULAV Asset Management first reported a position in LLY in Q2 2013 and has held it in 10 quarters since. The position peaked at $10.8M in Q2 2026. 4,624 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • EULAV Asset Management held 8,910 shares of Eli Lilly worth $10.3M as of Q3 2026.
  • EULAV Asset Management sold 100 Eli Lilly shares in Q3 2026, an estimated $118K.
  • Eli Lilly made up 0.37% of EULAV Asset Management's portfolio in Q3 2026, its #79 holding.
  • EULAV Asset Management first reported a position in Eli Lilly in Q2 2013 and has held it in 10 quarters since.
  • EULAV Asset Management's Eli Lilly position peaked at $10.8M in Q2 2026.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on EULAV Asset Management's 13F filing for Q3 2026, filed 23 Oct 2026.